Business Wire

Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis

Share

For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin"), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.

KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT® defucosylation technology to enhance its antibody dependent cellular cytotoxicity (ADCC) activity2. The combination of ADCC and antagonist activity against OX40 may suppress inflammatory responses found to be the cause of atopic dermatitis3-6.

The Phase 2 study was a multicenter, randomized, double-blind and placebo-controlled clinical study conducted in Japan, the United States, Canada, and Germany to investigate the efficacy and safety of KHK4083. Globally, 274 patients with moderate to severe atopic dermatitis, who were not adequately controlled with topical agents, were enrolled in the study.

In this study, all KHK4083 cohorts achieved superiority to placebo cohort for the primary endpoint of "percent change from baseline in Eczema Area and Severity Index (EASI)7 at 16 weeks” with statistical significance. In addition, there was significant difference in “the percentage of patients achieving an EASI-75 (EASI score of 75% or greater improvement from baseline) at 16 weeks” and “the percentage of patients achieving the Investigator's Global Assessment (IGA) of 0 or 1 with an improvement of 2 points or more at 16 weeks” in all KHK4083 cohorts compared to the placebo cohort. Further improvement in efficacy of KHK4083 was observed after week 16. Common treatment-emergent adverse events for KHK4083 cohorts were pyrexia, nasopharyngitis, worsening of atopic dermatitis and chills during the first 16 weeks. Pyrexia and chills events were mild to moderate in intensity, most of them were due to injection reaction and observed only after the first administration of the investigational product. There was no events of severe hypersensitivity reactions and no death observed in the study.

“The results of the KHK4083 Phase 2 study show that OX40 is a relevant target for atopic dermatitis and may provide a new treatment paradigm,” said the lead investigator of this study, Dr. Emma Guttman-Yassky, MD./PhD., System Chair for the Department of Dermatology and Waldman Professor of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai and Director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at Mount Sinai. “In addition to the primary endpoint, this study also showed progressive improvement in efficacy by continuous KHK4083 administration beyond 16 weeks and the potential for long-term sustained therapeutic effect after the completion of KHK4083 treatment.”

“We are very pleased with the results of this study assessing efficacy and safety of KHK4083 in chronic, recurrent, moderate to severe atopic dermatitis,” said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of Global R&D Division of Kyowa Kirin. “We look forward to sharing the results of the full analysis in the near future. I would like to express my deep gratitude to the medical professionals and patients for their participation in the study. We will continue KHK4083 development with the hope it can help patients in need.”

The full results of the study are planned to be presented through future academic conferences and publications.

The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Atopic Dermatitis

Atopic dermatitis is a disease in which the main lesion is an itchy eczema that repeatedly flares up and flares down, and many patients have a predisposition to atopic dermatitis (family and previous history, predisposition to produce IgE antibodies). It is an eczematous disease with a characteristic symmetrical distribution, and the site of predilection differs according to age. Characteristic eczematous lesions that develop in infancy or early childhood, remit in childhood, or recur without remission, and persist into adulthood, are seen chronically.

About OX40

OX40 is a co-stimulatory molecule that is one of the tumor necrosis factor receptor (TNFR) family member and plays an important role in maintaining T cell proliferation and survival by inhibiting apoptosis and in the formation of memory T cells. OX40 is expressed on the surface of effector T cells (CD4 positive) activated by antigens. It has been reported that effector T cells expressing OX40 are present in the lesions of atopic dermatitis3-6.

About Eczema Area and Severity Index(EASI)

EASI is an internationally used classification of atopic dermatitis severity and is recommended for use by Harmonising Outcome Measures for Eczema, an international group for standardizing clinical trial outcomes in atopic dermatitis7.

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with over 70-year heritage, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com.

References

  1. Decision Resources Group, Atopic Dermatitis/Atopic Eczema Disease Landscape & Forecast, December 2019
    © [2019] DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission.
  2. Shinkawa et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity. J. Biol. Chem., 278(5) 3466-3473, 2003
  3. Paterson DJ, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987; 24:1281–90.
  4. Guttman-Yassky E, Dhingra N, Leung DY. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013; 13:549-61.
  5. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014; 134:769-79.
  6. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015; 73:311-8.
  7. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index(EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group, Exp Dermatol, 2001; 10: 11-18.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Kyowa Kirin Tokyo Headquarter: Hiroki Nakamura, media@kyowakirin.com
Kyowa Kirin North America: Lauren Walrath, lauren.walrath.g4@kyowakirin.com
Kyowa Kirin International (EMEA): Stacey Minton, Stacey.Minton@kyowakirin.com

Investor Relations:
Tomomasa Yagisawa, ir@kyowakirin.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Heise Medien relies on the Xpublisher editorial system18.5.2021 15:04:00 CEST | Press release

Heise Medien GmbH & Co. KG, one of Germany’s leading tech industry publishers, succeeded in establishing transparent and well-organized content and media asset management together with a highly streamlined production process for its magazines by implementing Xpublisher. Xpublisher supports content utilization along the entire value chain, from planning, editorial creation, editing, and layout to the final publication, based on a “content first” approach. This enables Heise Medien to publish across multiple channels in a way that is highly efficient, cost effective, and error free. "We are pleased that Heise Medien trusts in our expertise and successfully automates their magazine production with our editorial system", says Matthias Kraus, CEO of Xpublisher. The numbers are a testament to the project’s success: Instead of the typical production phase of ten days, the first issue of c't was ready for printing in just nine days. In digital production, the company succeeded in both enhancin

Thales Announces New Solutions to Help Organisations Discover, Protect and Control Sensitive Data in Multicloud Environments18.5.2021 15:00:00 CEST | Press release

Thales today announced new data protection solutions for Google Cloud, Microsoft Azure, and Amazon Web Services, solidifying its role as a trusted third party for multicloud data security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005282/en/ © Thales With each cloud provider having unique data protection mechanisms and key management offerings, multicloud data protection presents a complex security challenge for organisations. Thales’ latest cloud data security solutions allow customers to maintain control of and manage their encryption keys, as well as manage access and authentication across hybrid and multicloud environments. “These capabilities are critical to cloud migration and security, especially with such accelerated growth in this area,” said Sunil Potti, Vice President and General Manager of Google Cloud Security. “True to our mission, we have forged this collaboration with Thales to further protect our

Trialbee Extends Executive Team and Launches Partner Program to Accelerate Growth, Expand Global Reach18.5.2021 15:00:00 CEST | Press release

Trialbee, a patient matching and enrollment platform, today announces key additions to its leadership team and a strategic partner program to further accelerate the company’s growth. These additions come during a period of unprecedented business results and will further scale the company’s global patient recruitment capabilities for clinical trials. Trialbee’s emergence as a trusted partner comes at a time when finding qualified patients and simplifying their journey into clinical research is more important than ever. Trialbee Hive™ utilizes real-world data (RWD) and advanced data science to model and expand patient targeting, providing greater awareness, inclusivity, and diversity of relevant patient populations. Interested patients are then engaged through Trialbee’s Candidate Manager platform that incorporates live nurse qualification and telehealth capabilities to refer study-ready patients into the trial, reducing site burden and enhancing enrollment outcomes. Four of the world’s

Styra Raises $40 Million in Series B Funding to Drive Access, Security and Compliance in Cloud-Native Applications18.5.2021 14:59:00 CEST | Press release

Styra, Inc., the founder of Open Policy Agent (OPA) and leader in cloud-native authorization, has raised a $40 million Series B funding round to continue driving the reinvention of policy and authorization for cloud-native applications. The round was led by Battery Ventures with participation from previous investors, A. Capital, Unusual Ventures, and Accel, as well as new investors at Capital One Ventures and Citi Ventures. With this funding, Dharmesh Thakker, General Partner at Battery Ventures, will be joining the Styra board. The round further solidifies its market leadership and provides capital to accelerate its founders’ vision—to create the standard for authorization—which started with OPA. OPA, initially proven out at scale by the likes of Netflix, Capital One, Atlassian, Pinterest and others, has now reached the point of over one million downloads per week. Styra has also seen exponential business traction in 2020, achieving 300% customer and commercial growth year-over-year,

Philip Morris International Reports Progress Toward Accelerating the End of Smoking18.5.2021 14:23:00 CEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today published its Integrated Report, a comprehensive overview of the company’s environmental, social, and governance (ESG) performance and its progress toward its purpose of delivering a smoke-free future. This includes its 2025 ambitions to have switched more than 40 million adult smokers to its smoke-free products, with half from non-OECD countries, and for smoke-free products to account for more than 50 percent of PMI’s total net revenues. Further accelerating PMI’s transformation, this year the company introduced two new 2025 ambitions, linked to its Business Transformation Metrics: for its smoke-free products to be available in 100 markets and for at least USD 1 billion in annual net revenues to come from “beyond nicotine” products. The Integrated Report also outlines case studies of early indications of PMI’s smoke-free products’ impacts in markets where such products have a meaningful presence. “I present this report with pride

CHRYSO Launches EnviroMix®, the First Global Range of Admixture Solutions and Services for Low-Carbon Concrete18.5.2021 14:00:00 CEST | Press release

CHRYSO, a leading player in the development of sustainable solutions in the construction industry, launches EnviroMix®, a global range of innovative products and services aimed at reducing and controlling the carbon footprint of concrete, dedicated to the ready-mix and precast concrete industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210518005573/en/ The development of low-carbon concrete, a major challenge for the construction industry. (Photo: Shutterstock) “The construction industry is accelerating its transformation to manage and reduce the environmental impact of its carbon footprint. CO2 footprint is a major challenge in the development of concrete formulations, coupled with the traditional properties of this material, and at the heart of our construction techniques (classes of strength and durability, workability, setting time, etc.)", states Frédéric Guimbal, Director of Concrete BU. In order to pick up the

Halliburton and TGS Collaborate to Advance Seismic Reservoir Monitoring18.5.2021 13:00:00 CEST | Press release

Halliburton Company (NYSE: HAL) and TGS-NOPEC Geophysical ASA (OSLO:TGS) today announced a collaboration to bring advanced seismic imaging to fiber optic sensing. The alliance will provide operators with advanced insight to determine their reservoir potential for oil and gas production or carbon storage. The Halliburton FiberVSP™ and Odassea™ distributed acoustic sensing solutions will now incorporate TGS’s seismic imaging workflows that process the entire seismic wavefield to generate high-resolution reservoir images. “We are excited to transform vertical seismic profiling to a full-field, digital, and intervention-less surveillance solution,” said Trey Clark, vice president of Wireline and Perforating. “Through our collaboration with TGS, we can now enable real-time monitoring of production across an entire field, allowing our customers to make better decisions and increase ultimate recovery.” “This solution enables enhanced reservoir understanding for our customers with a lower tota

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom